Overview

* Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln

* Company to be acquired by QOL Medical for $11.00 per share

* Gimoti patent extended to November 2038, ensuring exclusivity

Outlook

* Company expects acquisition by QOL Medical to close in Q4 2025

* Company anticipates expanded distribution through new pharmacy relationships

* Company believes acquisition will enhance growth potential under new leadership

Result Drivers

* SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships

* EXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distribution

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.45

Q3 Net -$1.20

Income mln

Q3 $5.40

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)